On May 27, 2025 GlyTherix Ltd reported a strategic supply agreement with Isotopia Molecular Imaging Ltd for the provision of Lutetium-177 (Lu-177) and Terbium-161 (Tb-161), key radioisotopes for advancing our targeted radiopharmaceutical therapies (Press release, Glytherix, MAY 27, 2025, View Source [SID1234653397]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This collaboration strengthens our ability to develop innovative cancer treatments and reinforces our commitment to delivering cutting-edge solutions to patients worldwide. Isotopia’s expertise in isotope production ensures a reliable and high-quality supply, supporting GlyTherix’s mission to transform precision oncology.

Together, we are pushing the boundaries of radiopharmaceutical innovation and building the next generation of cancer care.